Phase 2 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are able to give informed consent and agree to follow the rules and requirements of the trial.
- People who have been diagnosed with a type of lung cancer called non-squamous non-small cell lung cancer (NSCLC) that has spread locally or to other parts of the body.
- People whose lung cancer has a specific gene change (mutation) — called 19del, L858R, or T790M — confirmed by an approved laboratory.
- People who cannot tolerate, have refused, or are not suitable for standard chemotherapy.
- People whose cancer has stopped responding to a type of targeted therapy called EGFR-TKI, or who could not tolerate it; those with the T790M mutation must have already been treated with osimertinib or another third-generation EGFR-TKI.
- People with a general health/activity level rated 0 or 1 on the World Health Organization scale (meaning largely able to carry out normal daily activities).
- People with a life expectancy of more than 12 weeks at the time of starting the trial.
- People who have at least one measurable area of cancer that can be monitored.
- Women of childbearing potential who have a negative pregnancy test before starting and who are using highly effective contraception, or women with confirmed evidence that they cannot become pregnant.
- Men who are willing to use barrier contraception (such as condoms) during the trial.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose cancer has certain other specific gene changes, including RET rearrangement, BRAF V600E mutation, NTRK fusion, MET ex14 skip mutation, or MET amplification (confirm with trial site for exact testing details).
- People who have had another active cancer in the past 2 years.
- People who have had major surgery within 4 weeks before starting the trial.
- People who still have unresolved side effects from a previous cancer treatment.
- People with a past or current history of a lung condition called interstitial lung disease (ILD) or pneumonitis, including types caused by drugs or radiation that needed steroid treatment.
- People with severe or uncontrolled serious illnesses.
- People with certain heart-related conditions, including an abnormal heart rhythm measurement on an ECG, other important heart rhythm or electrical problems, or factors that increase the risk of heart rhythm complications (confirm with trial site for specific details).
- People with ongoing nausea and vomiting that cannot be managed, chronic gut/digestive diseases, difficulty swallowing, or who have had significant bowel surgery that could affect how the trial medications are absorbed.
- People with severe allergies to either of the trial medications, Sunvozertinib or Anlotinib.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Primary endpoints
ORR
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.